2018
DOI: 10.1016/j.eucr.2018.03.001
|View full text |Cite
|
Sign up to set email alerts
|

Malignant priapism in metastatic prostate cancer: A late event occurring early

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 3 publications
0
1
0
Order By: Relevance
“…In prostate cancer another option is hormone deprivation therapies which cut the source of cancerous cells growing stimulator such as antiandrogens, gonadotropin-releasing hormone (GnRH) agonists and 5α-reductase inhibitors, however their efficacy are not approved yet (13). Although pelvic radiotherapy have shown promising outcome, it can be accompanied by anatomical changes which might be troublesome for voiding of the patients (14). Hormonal therapies, on the other hand, have shown that they can affect the prognosis of prostate cancer and prolong the life expectancy (15).…”
Section: Discussionmentioning
confidence: 99%
“…In prostate cancer another option is hormone deprivation therapies which cut the source of cancerous cells growing stimulator such as antiandrogens, gonadotropin-releasing hormone (GnRH) agonists and 5α-reductase inhibitors, however their efficacy are not approved yet (13). Although pelvic radiotherapy have shown promising outcome, it can be accompanied by anatomical changes which might be troublesome for voiding of the patients (14). Hormonal therapies, on the other hand, have shown that they can affect the prognosis of prostate cancer and prolong the life expectancy (15).…”
Section: Discussionmentioning
confidence: 99%